Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Almirall S.A.
LBTSFAlmirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain. Address: Ronda General Mitre, 151, Barcelona, Spain, 08022
Analytics
Objectif de Cours de WallStreet
12.49 EURRatio C/B
–Rendement du dividende
1.72 %Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés LBTSF
Analyse des dividendes LBTSF
Croissance des dividendes sur 5 ans
–Croissance continue
1 annéeRatio de distribution Moyenne sur 5 ans
112 %Historique des dividendes LBTSF
Valorisation des titres LBTSF
financières LBTSF
Résultats | 2019 | Dynamique |